orientaciones provisionales, 8 de noviembre de 2020
This interim guidance is most useful for countries interested in monitoring relative circulations of influenza and SARS-CoV-2 viruses. The document provides practical information to maintain surveillance of influenza and monitor SARS-CoV-2 using e...xisting surveillance systems. It contains updated considerations for addressing disruptions in the influenza sentinel surveillance and extending to include COVID-19 wherever possible. Updated algorithms for testing of both influenza and SARS-CoV-2 for surveillance are also included. This document is an update of Operational considerations for COVID-19 surveillance using GISRS and GISRS for the upcoming influenza seasons during the COVID-19 pandemic
more
29 Dec 2021. Comprehensive slideset updated regularly to include the latest data and guidance on best practices for COVID-19 diagnosis and prevention of COVID-19 transmission.
GUIDE PRATIQUE À L’INTENTION DES PROGRAMMES DE LUTTE CONTRE LES MALADIES TROPICALES NÉGLIGÉES
This toolkit provides step-by-step guidance to NTD programme managers and partners on how to engage and work collaboratively with the WASH community to improve delivery of water, sanitation and hygien...e services to underserved population affected by many neglected tropical diseases. The toolkit is based on real-life programme experience, which users can match to their needs and local context. It includes a series of tools to help build multisectoral partnerships, mobilize resources, and design, implement and evaluate interventions.
more
Licensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP shall be used as a standard to justify GMP status,... which constitutes one of the elements of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, through the assessment of applications for manufacturing authorizations and as a basis for the inspection of manufacturing facilities. It may also be used as training material for government medicines inspectors, as well as for production, QC and QA personnel in the industry
more
Considerando los cambios estratégicos en el abordaje de la salud pública y de la atención primaria de la salud, la prevención y el control de la tuberculosis en Ecuador genera un cambio en la parte organizacional y en la prestación de servicios con enfoque en grupos vulnerables y/o con factores... de riesgo acorde a los ciclos de vida. Esta documento contempla una orientación apoyada en evidencia científica y otras recomendaciones en la práctica médica, basadas en el buen juicio clínico de quien la emplea como referencia, en las necesidades del afectado y en los recursos disponibles al momento de la atención, dando prioridad a la prevención, diagnóstico, tratamiento y control de la TB.
more
2ª edição atualizada.
O Manual de Recomendações apresenta as diretrizes nacionais para o controle da doença, que incluem procedimentos clínicos padronizados, procedimentos laboratoriais, sistema de vigilância, ações de biossegurança e organização de serviços. Apesar de conter as reco...mendações clínicas no que diz respeito à padronização de ações de busca de casos e tratamento, o manual está destinado às ações voltadas para a saúde pública e não pretende ser um guia clínico sobre a doença. Dessa forma, não substitui livros, textos e publicações acadêmicas que identifiquem boas práticas clínicas sobre a abordagem do sintomático respiratório e do paciente com tuberculose nos seus variados aspectos e especificidades.
more
Revista Peruana de Medicina Experimental y Salud Pública 2017 Vol 34 (2)
En el presente artículo se desarrolla la situación epidemiológica de la TB en el Perú al 2015, los avances en su control, de acuerdo a tres enfoques: biomédico, de gestión pública y de determinantes sociales de la salu...d, y plantea desafíos para hacer frente a la TB en el marco de la Ley 30287 y la estrategia "Fin de la Tuberculosis".
more
El Plan Estratégico Colombia Hacia el Fin de la Tuberculosis, 2016 –2025 es un instrumento para la gestión de los programas en los nivelesnacional y local en su objetivo de respondera los compromisos adquiridos por los países, para adoptarla Estrategia Mundial Fin de la Tuberculosi...s. La Estrategia se suma a los Objetivos de Desarrollo Sostenible (ODS),una de cuyas metas es el fin de las epidemias de malaria, VIH y tuberculosis para el 2030 (ODS 3). El Plan establece las metas a alcanzar por el Programa Nacional de Tuberculosis en el periodo 2016-2025, los objetivos y actividades para lograrlo y la forma para determinar que se ha logrado. El Plan permite guiar la toma de decisiones sobre la asignación de recursos, el establecimiento de prioridades y la definición de acciones. Para su elaboración se tomó como base la Estrategia Mundial Fin de la Tuberculosis,de la OMS y los componentes y procesos propuestos por la Guía Metodológica para la Construcción de Planes Estratégicos de la OMS.
more
O Protocolo de Vigilância Epidemiológica e Sanitária de Eventos Adversos Pós-Vacinação (EAPV), é o documento de referência nacional para a vigilância das vacinas COVID-19. Além disso, complementará, com os demais protocolos definidos pelo Ministério da Saúde, as ações empreendidas par...a o enfretamento da pandemia de Covid-19 no país.
O desenvolvimento e a operacionalização do Protocolo obrigam à definição clara de uma estrutura de liderança, coordenação e harmonização, bem como à identificação das entidades com responsabilidades no planejamento, na execução e na avaliação das atividades estabelecidas nas três esferas de gestão do Sistem Unico de Saude. Para tanto, este Protocolo preconiza o fortalecimento da integração dos atores do SUS, bem como de segmentos da sociedade brasileira, envolvidos direta ou indiretamente com a minimização de riscos e monitoramento de EAPV.
Este documento apresenta orientações gerais estruturantes e procedimentos para o funcionamento eficiente do sistema de farmacovigilância/vigilância de eventos adversos pós-vacinação (VEAPV) nas diferentes esferas de gestão do Sistema Unico de Saude, especificamente quanto as questões de segurança e queixas técnicas de vacinas.
more
The COVID-19 pandemic and subsequent public health guidance to reduce the spread of the diseasehave wide-reaching implications for children’s health and wellbeing. Furthermore, paediatric emergency departments(EDs) have rapidly adapted provision of care in response to the pandemic. This qualitativ...e study utilized insight frommultidisciplinary frontline staff to understand the changes in paediatric emergency healthcare utilization duringCOVID-19 the experiences of working within the restructured health system.
more
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat...ed: version 15 March 2022.
more
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
5 May 2021
This Information Note is intended to assist national TB programmes and health personnel worldwide to maintain essential tuberculosis (TB) services during the COVID-19 pandemic and in the recovery phase. It is important that recent progress made in TB prevention and care is not reversed b...y COVID-19. The WHO Global TB Programme, along with WHO regional and country offices, developed this note in response to questions received from Member States and other partners since the start of the pandemic. The note includes references to other published WHO information products relevant to TB practitioners. WHO continues to monitor the situation closely for any changes that may influence this note and will issue updates should any factors change.
more
BMZ Papier 1
Gesundheit ist nicht nur Voraussetzung für ein selbstbestimmtes Leben, sondern auch essenziell für die gesellschaftliche und nachhaltige wirtschaftliche Entwicklung in unseren Partnerländern. Die gegenwärtige COVID-19 Pandemie zeigt, welche Gefahren von Infektionskrankheiten ausge...-hen. Der Erreger der Pandemie SARS-CoV-2 gibt auch einen Hinweis auf die Bedeutung zoono-tischer, also zwischen Tier und Mensch übertragbarer, Krankheiten. Es ist zu erwarten, dass diese Art von Erregern in der Zukunft noch häufiger auftreten wird. Eine wachsende Weltbevölkerung, Klimawandel, steigende Mobilität, Vordringen des Menschen in bisher unberührte Lebensräume, industrielle Landwirtschaft und Nutztierhaltung sind Faktoren, die das Risiko für das Entstehen bzw. für eine schnelle Ausbreitung von Krankheitserregern erhöhen
more
Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.This guidance document outlines an approach to leverage existing surveillance systems for Severe Acute Respirato...ry Infection (SARI) to estimate COVID-19 vaccine effectiveness (VE) in preventing SARI associated with laboratory-confirmed SARS-CoV-2 using existing SARI surveillance systems. The approach uses the test-negative design to evaluate VE; cases are SARI patients who tested positive for SARS-CoV-2, and controls are SARI patients who tested negative for SARS-CoV-2.
more
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...fehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist.
more